Since 2003, multiple biologics targeting specific inflammatory pathways have been developed for severe asthma. Despite guideline-recommended selection based on clinical characteristics and biomarkers, a substantial proportion of patients respond inadequately and require switching to an alternative biologic [1]. In patients responding poorly to anti–IL-5/IL-5Rα biologics, switching to dupilumab may be beneficial: one study reported clinical remission in 43% of such patients, [2] and a multicentre retrospective study found 60.6% remained on dupilumab at 36 months [3].
